Monday 22nd January 2018
|Text too small?|
Blis Technologies reported a positive third quarter result but said that, combined with an ongoing recovery in the fourth quarter, won't offset a tough first half and it lowered full-year guidance.
The Dunedin-based company said revenue for the quarter ended Dec. 31 was $1.6 million, up 6 percent on the year. Earnings before interest, taxes, depreciation and amortisation were $200,000 and there was a small net profit, it said.
Based on known and expected orders for the final quarter Blis is forecasting "ongoing revenue recovery with double-digit growth compared to the same period last year, a positive ebitda and a net profit for the quarter."
However, "this will not be sufficient to fully offset the ebitda loss previously reported for the first half of the year," it said. Blis reported a first-half ebitda loss of $953,000 as trading revenue tumbled, in particular in its North American market.
The company now expects revenue "in excess of $5 million" and an ebitda loss below $500,000, it said.
It did not provide guidance in its first-half report in November, but in October said it expects the company's revenue for the year ending March 31 to be similar to the prior year with a small postive ebitda and a net deficit. Revenue in the prior year was $6.5 million.
Blis was set up to commercialise probiotic bacteria for use in consumer products for oral health, colds and flu, operates in Australasia, Asia, Europe and North America. Its shares last traded at 1.9 cents and have dropped 57 percent over the past 12 months.
No comments yet
Transpower seeks up to $125 mln in new bond ahead of November maturity
Chorus open to convergence in fixed, mobile networks, CEO McKenzie says
Metlifecare shares fall 4.8% as posts drop as first-half profit falls 66%
Chorus first-half profit drops 29% as wireless competition bites; signals job cuts in cost-cutting drive
February 26th Morning Report
CBL appoints voluntary administrators to 'preserve value' after interim liquidation
NZ dollar holds below 73 US cts as Fed chair Powell testimony comes into focus
World Week Ahead: Rate path check from Powell
RBNZ gets High Court order putting CBL Insurance into interim liquidation
MARKET CLOSE: NZ shares rise, led by Summerset, Metlifecare, Comvita falls after flagging poor season